India Gentamycin Market to be grow by CAGR of 6.31% during forecast period
Growing prevalence of
bacterial infections is expected to drive the India Gentamycin Market in the forecast period 2027-2031
According to TechSci Research report, “India Gentamycin
Market - By Region, Competition Forecast &
Opportunities, 2031F”, The India Gentamycin Market was valued at
USD 68.32 Million in 2025 and is expected to reach USD 97.87 Million by 2031,
growing with a CAGR of 6.31% in the forecast period.
The
India gentamicin market plays a vital role in the country’s pharmaceutical and
healthcare sectors, serving as a cornerstone in the treatment of
life-threatening bacterial infections. Gentamicin, a broad-spectrum
aminoglycoside antibiotic, is widely used in clinical settings for managing
severe infections such as septicemia, hospital-acquired pneumonia, complicated
urinary tract infections, and intra-abdominal infections. Its high efficacy
against Gram-negative bacteria makes it especially valuable in intensive care
units and neonatal care, where timely intervention is crucial. The drug’s
extensive usage in injectable form, which accounts for over 70% of its total
demand in India, is largely due to its poor oral bioavailability, necessitating
parenteral administration to ensure effective bloodstream absorption.
The market is predominantly driven by India’s large patient population, high prevalence of infectious diseases, and strong demand across both public and private healthcare systems. In-house manufacturing dominates the supply side, with leading pharmaceutical companies operating integrated facilities that produce both the active pharmaceutical ingredient (API) and final formulations. These companies benefit from economies of scale, low production costs, and adherence to stringent regulatory standards, enabling them to cater to both domestic demand and export markets. India currently contributes significantly to global gentamicin API supply, exporting to regions such as Africa, Southeast Asia, and Latin America where affordable antibiotics are in high demand.
Government initiatives such as the Pradhan Mantri Jan Aushadhi Yojana and the inclusion of gentamicin in the National List of Essential Medicines (NLEM) have ensured broad accessibility, especially in rural and underserved areas. Public procurement programs by state governments and central agencies have further boosted demand by securing large volumes of gentamicin injections for public hospitals and health centers.
Despite these strengths, the market faces notable challenges. Gentamicin’s known side effects—particularly nephrotoxicity and ototoxicity—require careful monitoring, limiting its use in outpatient settings and among vulnerable populations like the elderly and infants. Rising antimicrobial resistance (AMR) also poses a long-term threat, reducing the effectiveness of gentamicin against certain bacterial strains and prompting stricter stewardship protocols across hospitals. Regulatory price controls and competitive tendering in government contracts further constrain profit margins for manufacturers, discouraging smaller players from entering or expanding in the market.
Another emerging trend is the use of gentamicin in veterinary medicine, particularly in livestock and poultry farming. This segment is experiencing growth due to rising concerns about zoonotic infections and the need for reliable, affordable antibiotics in animal health. However, this also raises concerns about antibiotic overuse and the need for strict regulation to prevent AMR in the food chain.
Browse over XX market data Figures
spread through XX Pages and an in-depth TOC on "India Gentamycin Market ”
The India Gentamycin Market is segmented into source, form,
route of administration, distribution channel, application, regional
distribution, and company.
Based on distribution channel, offline channels
dominated the India gentamicin market, primarily due to the drug’s clinical use,
regulatory classification, and method of administration. Gentamicin is a
prescription-only antibiotic, most commonly administered via injection in
hospitals, clinics, and healthcare centers. As such, it is primarily
distributed through institutional sales, hospital pharmacies, and offline
retail pharmacies that can dispense medicines under medical supervision. Around
80–85% of gentamicin sales in India occur through offline channels, especially
within public sector hospitals under government procurement schemes.
Online pharmaceutical platforms contribute a smaller
share, largely limited to topical or ophthalmic gentamicin formulations, which
are less regulated and used for localized infections. However, injectable
gentamicin requires cold chain management and professional administration,
restricting its availability through e-commerce. Despite the growing digital
health trend, stringent prescription controls and handling requirements keep
offline channels firmly in the lead. Offline distribution is expected to continue
dominating due to gentamicin’s critical clinical use and logistical needs.
Based on application, Bacterial infections,
particularly severe Gram-negative bacterial infections, are the dominant
application segment in the India gentamicin market. Among these, sepsis holds
the leading share due to its life-threatening nature and the critical role
gentamicin plays in hospital-based treatment protocols. Sepsis accounts for
approximately 30–35% of gentamicin usage, especially in intensive care units,
neonatal care, and emergency departments. Its rapid bactericidal action makes
gentamicin a preferred choice in combination therapies for early empirical
treatment of bloodstream infections.
While gentamicin is also used for urinary tract
infections, meningitis, and skin or soft tissue infections, these contribute
smaller portions to overall demand. In neonatal and pediatric settings,
gentamicin is widely prescribed for suspected sepsis, often paired with
ampicillin. The drug’s injectable format is well-suited for inpatient care,
which is typically required for managing sepsis. Given the high mortality risk
and urgency associated with sepsis, it remains the most critical and
volume-driven segment in the gentamicin market.
Based on region, North India is the fastest-growing
region in the India gentamicin market, driven by expanding healthcare
infrastructure, rising patient population, and increasing government investment
in public health services. States like Uttar Pradesh, Delhi, Punjab, and
Haryana are witnessing a surge in hospital admissions and treatment of
infectious diseases, leading to higher demand for antibiotics such as
gentamicin, especially in injectable form.
The growth is also fueled by the rapid development of
government-run healthcare schemes that prioritize access to essential
medicines, including gentamicin, in rural and semi-urban areas. North India has
a high incidence of sepsis, neonatal infections, and hospital-acquired
infections, making gentamicin a key part of treatment protocols. Pharmaceutical
companies are expanding distribution networks in the region to meet rising
demand from both public sector hospitals and private clinics. With ongoing investments
in healthcare access and medical infrastructure, North India is expected to
continue outpacing other regions in gentamicin market growth.
Major companies operating in India Gentamycin
Market are:
·
Taj Pharmaceuticals
Ltd
·
Bayer India Ltd.
·
Zydus Cadila
Healthcare Ltd.
·
Neon Laboratories
Ltd.
·
Hetero Healthcare
Ltd.
·
Gracure
Pharmaceuticals Ltd.
·
Intas
Pharmaceuticals Ltd.
·
Alembic
Pharmaceuticals Ltd.
·
Fresenius Kabi India
Pvt. Ltd.
·
Nestor
Pharmaceuticals Ltd
Download Free Sample Report
Customers can also request for 10%
free customization on this report.
“The pharmaceutical manufacturing base in India plays a crucial role in both domestic supply and international export of gentamycin formulations and active pharmaceutical ingredients (APIs). Indian manufacturers benefit from cost-effective production capabilities and a well-established regulatory framework, enabling them to serve global markets in Africa, Southeast Asia, and the Middle East. Despite its advantages, the gentamycin market faces challenges such as concerns over toxicity, particularly nephrotoxicity and ototoxicity, which limit its use in certain patient populations. Additionally, increasing antimicrobial resistance (AMR) has prompted more cautious prescribing patterns, with physicians emphasizing stewardship practices. However, the Indian gentamycin market is expected to grow at a moderate pace, driven by the rising incidence of hospital-acquired infections, the expanding pharmaceutical export base, and ongoing investments in public health programs. Innovations in formulation and delivery methods may also enhance its clinical use, ensuring gentamycin remains an important part of India’s antibiotic arsenal.” said Mr. Karan Chechi, Research Director of TechSci Research, a
research-based management consulting firm.
“India Gentamycin Market By Source (In-house v/s Contract Manufacturing Organizations), By Form (Eye Drops, Tablet, Capsule, Syrup, Injection, Cream, Gel, Ointment, Others), By Route of Administration (Ophthalmic, Intravenous, Topical, Oral, Others), By Distribution Channel (Online v/s Offline), By Application (Bacterial Infection, Urinary Tract Infection, Sepsis, Meningitis, Skin or Soft Tissue Infection, Upper Respiratory Tract Infection, Others), By Region, Competition, Forecast & Opportunities, 2021-2031F”, has evaluated the future growth potential of India Gentamycin
Market and provides statistics & information on
market size, structure and future market growth. The report intends to provide
cutting-edge market intelligence and help decision makers take sound investment
decisions. Besides, the report also identifies and analyzes the emerging trends
along with essential drivers, challenges, and opportunities in India Gentamycin
Market.
Contact
TechSci
Research LLC
420
Lexington Avenue, Suite 300,
New
York, United States- 10170
Tel: +1-332-258-6602
Email: [email protected]
Website: www.techsciresearch.com